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Amyotrophic lateral sclerosis (ALS) is an adult-onset disease characterized by the selective degeneration of motor
neurons in the brain and spinal cord progressively leading to paralysis and death. Current diagnosis of ALS is based on
clinical assessment of related symptoms. The clinical manifestations observed in ALS appear relatively late in the disease
course after degeneration of a significant number of motor neurons. As a result, the identification and development of
disease-modifying therapies is difficult. Therefore, novel strategies for early diagnosis of neurodegeneration, to monitor
disease progression and to assess response to existing and future treatments are urgently needed. Factually, many
neurological disorders, including ALS, are accompanied by skin changes that often precede the onset of neurological
symptoms. Aiming to generate an innovative human-based model to facilitate the identification of predictive
biomarkers associated with the disease, we developed a unique ALS tissue-engineered skin model (ALS-TES) derived
from patient’s own cells. The ALS-TES presents a number of striking features including altered epidermal differentiation,
abnormal dermo-epidermal junction, delamination, keratinocyte infiltration, collagen disorganization and cytoplasmic
TDP-43 inclusions. Remarkably, these abnormal skin defects, uniquely seen in the ALS-derived skins, were detected in
pre-symtomatic C9orf72-linked ALS patients carrying the GGGGCC DNA repeat expansion. Consequently, our ALS skin
model could represent a renewable source of human tissue, quickly and easily accessible to better understand the
physiopathological mechanisms underlying this disease, to facilitate the identification of disease-specific biomarkers,
and to develop innovative tools for early diagnosis and disease monitoring.
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Extracellular matrixIntroduction
Among neurological disorders, neurodegenerative dis-
eases are becoming more and more prominent because
of their severity and increasing frequency in aging po-
pulations. At present, the causes and pathogenic me-
chanisms of these diseases remain largely unknown. In
addition, these diseases are currently incurable and diffi-
cult to diagnose before a late stage due to lack of efficient* Correspondence: francois.gros-louis@fmed.ulaval.ca
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Amyotrophic lateral sclerosis (ALS) is an adult-onset neu-
rodegenerative disease characterized by the selective de-
generation of motor neurons in the brain and spinal cord
resulting in progressive paralysis and death [1]. The life-
time risk to develop the disease is approximately 1 in 1000
[1]. The median survival is approximately 2 years from
diagnosis and 3 years from symptom onset. To date, there
is no treatment that will meaningfully alter the course of
this disease.
Current diagnosis of ALS is based on clinical assess-
ment of related symptoms (Additional file 1: Table S1)
[2]. The clinical manifestations observed in ALS appear
only after degeneration of a significant number of motoris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of disease-modifying therapies is difficult, making ALS
an incurable disease and a serious challenge for neurolo-
gists. The latency between the first symptoms and a for-
mal diagnosis of ALS has remained unchanged for more
than a decade and ranges from 8.0 to 15.6 months [2].
At such a late stage, a large proportion of motor neu-
rons have already been lost. Therefore, novel disco-
veries of sensitive and specific biomarkers for ALS are
needed to facilitate diagnosis at early stages, monitor
disease progression, and assess response to existing and
future treatments.
In the initial stages, ALS is characterized predomin-
antly by a heterogeneous presentation of symptoms.
Most patients display cramps, weakness and muscle at-
rophy of the hands and feet progressing to the forearms,
shoulder and legs eventually leading to complete paraly-
sis. Some patients have their bulbar muscles primarily
affected, influencing speech and swallowing. In the ma-
jority of cases, cognitive functions are relatively intact
with subtle cognitive changes being observed in 30-50%
of cases; albeit comorbidity between frontotemporal de-
mentia (FTD) and ALS is observed in 25% of cases [3].
While motor neuron degeneration remains the central
component, there is considerable phenotypic variability
including site of onset, survivorship and the presence or
absence of cognitive impairment. ALS can thus be jus-
tifiably considered a heterogeneous disorder sharing in
common the degeneration of motor neurons. This syn-
drome is currently unified by the post mortem finding of
ubiquitinated TDP-43 cytoplasmic inclusions in motor
neurons of the central nervous system (CNS) in post-
mortem human pathologic tissues, a pathological hall-
mark now commonly found in the majority of familial
ALS (FALS) cases with or without TARDBP mutations,
and in sporadic ALS (SALS) cases [4-14]. In healthy
motor neurons, TDP-43 is typically localized to the nu-
cleus. TDP-43 thus becomes a potential marker associated
with the vast majority of ALS cases. At the moment, since
cytoplasmic TDP-43 inclusions are only found in post-
mortem CNS tissues, there are two major limitations of
using TDP-43 as a potential biomarker of the disease.
First, brain and spinal cord biopsies are too invasive and
as a consequence longitudinal studies become impossible.
Secondly, the different sites of onset, as well as the hete-
rogenous spreading, make it difficult to standardize the
choice of the site of biopsy.
The non-cell autonomous toxicity paradigm in ALS
has been well establish as they are increasing evidences
that it is the convergence of damage developed within
multiple cell types, including within neighboring non-
neuronal supporting cells, which is crucial to neuronal
dysfunction in ALS [15-21]. The involvement of other
cell types reveals certainly new perspectives to betterunderstand this disease. Due to the common embryonic
origin of both skin and neural tissue from the ectoder-
mal germ layer, many neurological disorders, including
ALS, are accompanied by skin changes that often pre-
cede the apparition of neurological symptoms [22]. Aim-
ing to generate an innovative human-based model and
to identify predictive biomarkers associated with the dis-
ease, we developed a unique ALS tissue-engineered skin
model (ALS-TES), derived from patient’s own cells. Our
results show that our ALS-TES present a number of
striking features uniquely seen in ALS-derived skins.
The identification of biomarkers in ALS has been a
very active area of investigation, employing transcrip-
tional studies, protein profiling in blood and CSF, im-
aging, and electrophysiological techniques [23]. While
these techniques have identified some potential ALS
biomarkers, so far none have proven to be clinically
useful. Our results show that it is possible to detect a
number of abnormal features associated with ALS using
our tissue-engineered skin model. Consequently, our
ALS-TES model could represent a renewable source of
human tissue, quickly and easily accessible to better un-
derstand the physiophatological mechanisms underlying
these diseases, to identify predictive disease biomarker
and hopefully to develop innovative tools for disease
monitoring and drug screening.
Materials and methods
Patients
Cases were recruited through the designated ALS clinics
in Quebec (Drs Dupré and Rouleau). Every index case
met the El Escorial criteria for clinically definite, pro-
bable or laboratory supported ALS (Additional file 1:
Table S1). All cases signed a consent form approved by
our Institutional Ethics Committees (Comité d'éthique
de la recherche du CHU de Québec) prior to being en-
rolled in the study and were recruited on a voluntary
basis. Skin biopsies were collected from affected and un-
affected individuals (Table 1). Besides collecting skin bi-
opsies, blood samples were also collected and used for
DNA extraction and patient’s genotyping. In totals 6
SALS (Table 1), 6 FALS-linked C9orf72 patients (Table 1
and Additional file 2: Figure S1) and 6 control indi-
viduals were recruited. Relative controls, matching for
both environmental exposures and genetic background
as well as with socio-economic status, ethnicity and
age, have been also recruited for this study. This type of
controls represents the perfect group in terms of
matching for age, sex ratio, ethnicity and environmental
exposures [24].
Skin biopsies and cell extraction/culture
For each participant, two skin biopsies were collected
using a 6-mm diameter punch biopsy. All skin biopsies
Table 1 Data information on ALS patients and controls recruited in the study
ID number Biopsy location Sex Age at sampling Current age Age of death Clinical status Genetic status
SALS 1 Arm M 48 NA 49 Affected No known ALS-associated mutations
SALS 2 Arm M 34 NA 34 Affected No known ALS-associated mutations
SALS 3 Arm M 64 NA 64 Affected No known ALS-associated mutations
SALS 4 Arm F 54 NA 54 Affected No known ALS-associated mutations
SALS 5 Arm M 59 NA 59 Affected No known ALS-associated mutations
SALS 6 Arm F 58 NA 58 Affected No known ALS-associated mutations
C9-S000005 Arm F 63 65 NA Clinically unaffected C9orf72 expansion
C9-S000008 Arm F 47 49 NA Clinically unaffected C9orf72 expansion
C9-S000009 Arm F 59 60 NA Affected C9orf72 expansion
C9-S000012 Arm M 52 54 NA Clinically unaffected C9orf72 expansion
C9-S000013 Arm F 49 51 NA Clinically unaffected C9orf72 expansion
C9-S000014 Arm M 46 47 NA Clinically unaffected C9orf72 expansion
Ctrl 1 Arm F 55 NA NA Control NA
Ctrl 2 Arm F 48 NA NA Control NA
Ctrl 3 Arm M 50 NA NA Control NA
Ctrl 4 Arm M 62 NA NA Control NA
Mui638x Arm F 38 NA NA Control NA
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Skin cells (fibroblasts and keratinocytes) were isolated in
order to generate tissue-engineered skin derived from
each cases and subjects as previously described [25].
Briefly, the skin biopsies were incubated with 0,05%
thermolysine (Sigma, Oakville, QC, Canada), overnight
at 4°C, in order to facilitate the mechanical separation of
the epidermis from the dermis. Then, fibroblasts and
keratinocytes were isolated from the dermis and the epi-
dermis respectively after treatment with 0,2 IU/mL col-
lagenase H (Roche, Missisauga, Ontario, Canada) and
with 0,05% trypsin (Intergen lot: xt20012, New-York,
USA), 0,01% EDTA (J.T. Baker, Center Valley, PA, USA).
Cultured fibroblasts, grown in DMEM (Dulbecco-Vogt
modification of Eagle's medium) (Invitrogen, Burlington,
ON, Canada) supplemented with 10% Fetal Calf Se-
rum (FCS) (Invitrogen), 100 IU/ml penicillin G (Sigma,
Oakville, QC, Canada) and 25 μg/ml gentamicin (Schering,
Pointe-Claire, QC, Canada) in 8% CO2 at 37°C, at pas-
sage five were seeded at a concentration of 1,5 × 105
cells on tissue culture dishes. Keratinocytes were see-
ded at 8 × 105 cells on a feeder layer of irradiated 3T3
mouse fibroblasts and were cultured in a combination
of Dulbecco-Vogt modification of Eagle's medium with
Ham's F12 (3:1) supplemented with 5% Fetal Clone II
serum (Hyclone, Scarborough, Ontario, Canada), 5 μg/mL
insulin (Sigma Oakville, Canada), 0.4 μg/mL hydrocor-
tisone (Calbiochem, EMD Biosciences, Gibbstown, NJ),
10 − 10 M cholera toxin (MP Biomedicals, Montréal,
Québec, Canada), 10 ng/mL human epidermal growthfactor (Austral Biological, San Ramon, CA), 100 IU/mL
penicillin G (Sigma), and 25 μg/mL gentamicin (Schering).
Production of tissue-engineered skin equivalents
At confluence, fibroblast medium was supplemented with
50 μg/ml of ascorbic acid (Sigma, Oakville, Qc, Canada)
for 28 days in order to induce secretion of extracellular
matrix (ECM) proteins and to form a fibroblast sheet.
Three fibroblast sheets were superimposed and cultured
for 7 additional days to allow sheet adhesion. Isolated ker-
atinocytes at passage three were seeded on top of the ma-
ture fibroblast sheets at a concentration of 1 × 105 cells
to form a new epidermal layer. The reconstructed skin
equivalent was then cultivated for another week prior to
cultivate the skin equivalents at the air-liquid interface
in order to enhance formation of the stratum corneum
(outermost layer of the epidermis) for two other weeks.
See Additional file 3: Figure S2 for more details.
Autopsy procedure
The autopsy procedure in brief is that the spinal verte-
brae are exposed by a standard dorsal approach and then
sectioned through the vertebral foramina. The posterior
vertebral arcs are then removed en bloc and the dural
sac exposed. The spinal cord is sectioned in the mid cer-
vical region to avoid further dissection of the neck. The
spinal cord from mid-cervical region to filum terminale
is then removed within the dural sac with short seg-
ments of peripheral nerve and spinal ganglia. The mid
and lower cervical cord is often submitted for research
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examination occurs after fixation of the thoracic, lumbar
and sacral spine within the dural sac in a dedicated
chamber. The dural sac is pinned at either end to pre-
vent retraction during fixation.
Immunohistochemistry (IHC)
IHC was performed on 5-μm thick sections subsequently
fixed in 4% paraformaldehyde dissolved in phosphate
buffer for 2 h at room temperature or overnight at 4°C.
Sections were first quenched in 0.3% H2O2 for 30 min,
permeabilized in 1% Tween 20 for 10 min, blocked in
5% normal goat serum for 1 h, and then incubated with
the primary rabbit anti-TDP43 antibody (cat# 12892-1-
AP, 1:1000, Proteintech Group Inc., Chicago, IL, USA)
for 16 h at 4°C. Visualization was made by incubating
the slides with a biotinyled goat anti-rabbit secondary
antibody coupled to horseradish peroxidase (1:500,
Jackson Immunoresearch Laboratories, West Grove, PA,
USA). Please note that the commercial TDP-43 antibody
used in this study recognizes the cleavage product of
20-30 kDa in addition to the native and phosphorylated
forms of TDP-43.
Masson’s trichrome staining
For Masson’s trichrome staining, ALS-TES were fixed in
Histochoice (Amresco, Solon, OH) and embedded in
paraffin. Microtome sections (5-um thick) were stained
with Masson’s trichrome using Weigert’s hematoxylin,
fuchsin-ponceau, and aniline blue stains. Deparaffiniza-
tion of the tissues were done by incubating the slides in
toluene (Chaptec, Pointe-Aux-Trembles, Québec, Canada)
for 10 minutes (2 times 5 minutes) followed by 20 quick
in and out dips in 99% ethanol (Les Alcools Commer-
ciales, Brampton, Ontario, Canada). Slides were then incu-
bated for 10 minutes in Weigert's Hematoxylin (Millipore,
Darmstadt, Germany) and washed for 5 minutes under
running tap water. Weigert's Hematoxylin solution was
prepared as followed: 200 ml of solution 1 (Millipore,
Cat. 7341×-71), 200 ml of solution 2 (Millipore, Cat.
7342×-71) and 1 ml of chlorhydric acid 2 N (Fisher Scien-
tific, Ottawa, Ontario). A second incubation in Fuchsin-
Ponceau stain solution for 5 minutes followed by 10 quick
in and out dips in 0,1% acetic acid (diluted in water) was
also performed. Fuchsin-Ponceau solution was prepared
as followed: 400 mL ddH2O, 0,13 g fuchsine acid (Sigma,
Cat. F-8129), 0,27 g xylidine ponceau (Sigma, Cat. P2395)
and 0,8 mL glacial acetic acid (J.T. Baker, Center Valley,
PA, USA, Cat. 9508). Slides were then incubated in freshly
made 5% phosphomolybdic acid for 6 minutes followed by
10 quick in and out dips in 0,1% acetic acid (diluted in
water) prior another series of 10 dips in distilled water.
Phosphomolybdic acid solution was prepared as followed:
200 mL ddH2O, 10 g phosphomolybdic acid (Alfa aesar,Ward Hill, MA, USA, Cat. 56166). A final incubation in
aniline blue for 5 minutes followed by 10 quick dips
0,1% acetic acid (diluted in water) and 10 other quick
in and out dips in ethanol 99% was also carried out.
Aniline blue solution was prepared as followed: 400 mL
of boiling ddH2O, 4 g aniline blue (Fisher Scientific,
Ottawa, Ontario, Cat. A967), 4 mL glacial acetic acid.
Slides were dipped 10 times in toluene and mounted
using mounting media (Sigma, Oakville, Québec, Canada).
Slides were stored at room temperature prior microscopy
analysis.
Immunofluorescence (IF)
IF was performed on 7-μm thick sections subsequently
fixed in 4% paraformaldehyde dissolved in phosphate
buffer for 2 h at room temperature or overnight at 4°C.
Sections were then washed, permeabilized in 1% Tween
20 for 10 min, blocked in 5% normal goat serum for
1 h, and then incubated with the primary rabbit anti-
TDP43 antibody (1:500, Proteintech Group Inc., Chicago,
IL, USA) for 16 h at 4°C. Sections were then washed
and incubated for 1 h at room temperature in Alexa
488- or Alexa 598-conjugated anti-rabbit secondary an-
tibodies diluted in blocking solution (1:500; Molecular
Probes). Imaging was performed using an LSI 700 con-
focal microscope with Metamorph imaging software
(Zeiss).
Subcellular fractionation of TES and Western blotting
Whole protein lysate from reconstructed skin equiva-
lents were extracted by cryogenic homogenization of the
tissues using the CryoMill (Retsch) enabling grinding of
tough, soft and elastic materials such as skin tissues into
a fine recoverable powder. The cryomilled tissues were
resolubilized in TNGT lysis buffer (50 mM Tris-HCl
pH 7,4; 100 mM NaCl; 10% Glycerol; 1% Triton-X). The
mix was then centrifuged at >20 000 rpm for 24 min at
4°C to separate supernatant (cytoplasmic fraction) and
pellet (nuclear fraction). The nuclear pellet was then
washed and resuspended in SUB lysis buffer (0,5% SDS,
8 M Urea, 2% b-mercapethanol in apyrogenic water).
Total protein was quantified by the Lowry method and
diluted in loading buffer (15% glycerol, 5% SDS, 80 mM
Tris–HCl, pH 6.8, 5% β-mercapto-ethanol and 0.01%
bromophenol blue). Each sample (25 μg) was run on a
14% SDS/glycine polyacrylamide gel and then trans-
ferred electrophoretically to a PVDF membrane (Biorad,
Hercules, CA, USA). The blots were blocked in 5% non-
fat milk/0.1% Tween 20 in phosphate-buffered saline
(PBS) and probed with polyclonal anti-rabbit TDP-43
antibody (Proteintech Group Inc., Chicago, IL, USA) di-
luted 1:500 in the blocking buffer. Immunodetection was
performed with a donkey anti-rabbit-HRP-labelled sec-
ondary antibody (1:1000, Thermo Scientific, Rockford,
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ClarityTM Western ECL Substrate (Biorad, Hercules,
CA, USA). The blots were then re-probed with an anti-
b-actin antibody (1:6000, Abcam) to document equal
loading.
Results
Structural abnormalities detected in ALS-TES by IHC
Masson’s trichrome is a special stain which is typically
used to characterize and discriminate between various
connective and soft tissue components. It is often uti-
lized as the stain of choice of distinguishing histological
changes in tumors, connective tissue diseases, muscle
and fibroblast tumors, renal diseases and dermatology
cases. Masson’s trichrome staining repeatedly revealed
evident structural abnormalities uniquely detected in
ALS-TES including an undifferentiated epidermis, cohe-
sive failure of the stratum corneum, abnormal dermo-
epidermal junction, delamination, keratinocyte infiltration,Figure 1 Structural abnormalities detected in ALS-derived tissue engi
derived tissue-engineered skins when cultured at the air-liquid interface. b)
blue and epidermis (EP) in purple, revealed a number of structural abnorm
junctions, delamination, abnormal collagen organization, keratinocyte infiltr
FALS- and SALS-derived skins. In contrast control-derived reconstructed ski
organized dermis.as well as collagen misorganization in both C9orf72 FALS-
and SALS-derived skins (Figure 1 and Additional file 4:
Table S2). In contrast, control-derived tissue engineered
skins showed a well-developed and differentiated epider-
mis and highly organized dermis.
TDP-43 cytoplasmic inclusion detected in ALS-TES
derived skin
In order to determine if cytoplasmic TDP-43 aggregates
can be detected in ALS-TES, 7-μm thick tissue sections
were prepared and stained with commercial TDP-43 po-
lyclonal antibody. Interestingly, TDP-43 cytoplasmic ag-
gregates, characteristic of ALS pathology, were detected
in SALS-derived skins by indirect immunofluorescence
and standard microscopy (Figure 2). These results were
also further confirmed by confocal microscopy, using
25-um thick sections (Additional file 5: Figure S3). To
our knowledge, it is the first time that cytoplasmic TDP-
43 aggregates are detected outside of the nervous systemneered skins. a) Macroscopic pictures of control-derived and ALS-
Masson’s trichrome colorations, specifically staining the dermis (DE) in
alities including undifferentiated epidermis, abnormal dermo-epidermal
ation and cohesive failure of the stratum corneum (SC) in both C9orf72
ns showed a well-developed and differentiated epidermis and highly
Figure 2 Cytoplasmic TDP-43 accumulation detected in SALS- and C9orf72 FALS-derived tissue-engineered skins. Indirect
immunofluorescence analysis using anti-TDP43 antibody (green) counterstained with DAPI (blue) revealed cytoplasmic TDP-43 accumulation in
SALS-derived as well as in C9orf72 FALS-derived tissue-engineered skins. Note that representative pictures of 7-um thick tissue-sections were
stained and visualized using a standard epifluorescent microscope. Each picture was taken using the same microscope, camera and exposure
settings. Scale bar (white): 10 μm.
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trast, no TDP-43 abnormal cytoplasmic accumulation
was observed in control-derived reconstructed skin. To
further confirm our results and determine if cytoplasmic
TDP-43 can also be detected in non-symptomatic pa-
tients, we have generated C9orf72 FALS-derived TES.
Five out of six generated C9orf72-TES were derived from
non-symptomatic patients carrying the GGGGCC DNA
repeat expansion (Additional file 2: Figure S1; Table 1).
Remarkably, cytoplasmic TDP-43 inclusions were detectedFigure 3 Cellular counts and Western blots quantification of TDP-43 c
cytoplasmic TDP-43 inclusions. 200 nuclei were counted for each of the ge
Subcellular fractionation (cytoplasmic fraction vs nuclear fraction) of total p
C9ORF72-derived TES and SALS-derived TES (n = 5 for each group) was per
fractionated sample was quantified using ImageJ after normalization again
after. *correspond to a P value < 0.05.by standard immunofluorescence analysis in both symp-
tomatic and yet non-symptomatic C9orf72-linked ALS
patients carrying the expansion (Figure 2). Actually,
around 30% of the fibroblasts within the C9orf72- and
SALS-derived skins presented cytoplasmic TDP-43 po-
sitive inclusions while only 4% of the fibroblasts in
the control-derived skins demonstrated TDP-43 cyto-
plasmic inclusions (Figure 3A). Validation of these results
were done by Western blotting after proper fraction-
ation of the cytoplasmic and nulear fractions (Figure 3B;ytoplasmic accumulation. a) Percentage of cell with positive
nerated tissue-engineered skins. *correspond to a P value < 0.01. b)
rotein extracted from ALS-fibroblast (2D culture), control-derived TES,
formed and loaded on a regular SDS-PAGE. TDP-43 expression in each
st actin. Equal amount of proteins was used as shown on western blots
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TDP-43 inclusions were only detected in our three di-
mensional (3D) ALS-TES model and were not detected
in patient’s fibroblasts alone standard two dimensional
(2D) cell culture indicating that our 3D skin model is
necessary to observe the described phenotype (Figure 4).
Western immunoblots, detected with nuclear (anti-nu-
clei antibody, clone 235-1, Millipore: cat# MAB1281)
and cytoplasmic (anti-GAPDH antibody, AbD Serotec:
cat# AHP1628) markers, revealed that our cytoplasmic
fraction was completely free of nuclear protein indi-
cating that the detected cytolasmic TDP-43 signal was
not due to a contamination of the fraction with nuclear
proteins (Additional file 6: Figure S4).Figure 4 Nuclear TDP-43 expression in C9orf72 fibroblasts
cultured cells. Indirect immunofluorescence using anti-TDP43
commercial antibody (green) conterstained with DAPI (nucleus)
revealed no cytoplasmic TDP-43 accumulation in C9orf72 cultured
fibroblasts collected from symptomatic and non-symptomatic
C9orf72 FALS patients. These results indicate that the described 3D
tissue-engineered skin model, allowing for cell-to-cell and cell-to-
matrix interactions, is necessary to observe the pathological
cytoplasmic accumulation of TDP-43. Scale bar (white): 10 μm.TDP-43 cytoplasmic inclusion detected in native skin
biopsies and in post-mortem CNS tissue collected from
ALS patients
To further confirm our results, we undertook immunohis-
tochemistry colorations, generally the method of choice in
hospital pathological departments, on native skin biopsies
collected from the corresponding ALS patients as well as
on post-mortem spinal cord tissues when available. The
IHC analysis confirmed the presence of cytoplasmic TDP-
43 skein-like inclusions in the fibroblasts of the native
skin biopsies taken from living SALS patients (Figure 5;
Additional file 7: Figure S5). Moreover, round TDP-43
cytoplasmic inclusions in the dentate gyrus’s granular
layer as well as skein-like TDP-43 cytoplasmic positive
inclusions in neurons present in the ventral horn of the
spinal cord were also detected by the neuropathologists
after formal autopsies (Figure 5).
Discussion
Here we report the generation and characterization of a
novel in vitro tissue-engineered skin model to study
ALS. Of particular interest, cytoplasmic TDP-43 inclu-
sions, a well-established pathological feature of ALS,
were uniquely seen in the ALS-derived TES as well as in
native biopsies collected from the corresponding ALS
patients. It has been previously shown that TDP-43 nu-
clear overexpression with no cytoplasmic inclusions can
be detected in native skin biopsies collected from ALS
patients [26]. It has also been shown that some aspects
of TDP-43 proteinopathies, including increased TDP-43
nuclear expression and decreased motor neurons sur-
vival, can be detected in motoneuronally differentiated
induced pluripotent stem cells [27,28]. However, we re-
port here for the first time cytoplasmic TDP-43 accumu-
lation in cells outside of the nervous system detected in
both skin biopsies taken from ALS patients and in our
patients-derived skin model. Interestingly, the TDP-43
mislocalization detected in our ALS-TES was observed
relatively early in the disease process. They were in fact
detected in the SALS-derived skins, long before the end
stage of the disease, and in pre-symptomatic C9orf72-
linked FALS patients carrying the GGGGCC hexanu-
cleotide DNA expansion. Furthermore, our ALS-TES
also presents a number of abnormal ECM-related fea-
tures including epidermal undifferentiation, abnormal
dermo-epidermal junction, delamination, keratinocyte
infiltration and collagen disorganization. Interestingly,
the cytoplasmic TDP-43 inclusions were also detected in
CNS tissues by the neuropathologist after formal autop-
sies. Note also that the pre-symptomatic C9orf72-linked
patients are still alive and have not yet developed any
motor or dementia associated symptoms.
Although the detection of TDP-43 mislocalization
in native skin biopsies presents a potential diagnostic
Figure 5 Cytoplasmic TDP-43 detection in native skin biopsies and corresponding CNS tissues in SALS patients. Immunohistochemistry
analysis, using anti-TDP-43 antibody, revealed the presence of TDP-43 cytoplasmic accumulation in both native skin biopsies (b) and post-mortem
(c) spinal cord tissues collected from SALS patients. Such TDP-43 cytoplasmic accumulation was not detected in control individuals (a).
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limits the number of techniques used to validate the ob-
served results. In contrast, the use of an in vitro tissue-
engineered skin model presents a renewable source of hu-
man tissue allowing for the extensive testing required for
the development of a novel in vitro validated diagnostic
method. Our ALS-TES model would therefore provide a
unique and innovative model to fully study the relation
between skin changes and ALS, as well as identifying and
validating specific ALS biomarkers for early diagnosis, to
follow disease progression or to assess response to existing
and future treatments. Such validated biomarkers, which
can be detected outside the nervous system using easily
accessible tissue, have never been described thoroughly in
ALS. The development and application of more efficient,
non- or minimally-invasive detection techniques in ALS
has become crucial for biomarker-driven therapeutic dis-
covery and also to monitor patient’s response to disease-
modifying therapies.
Tissue engineering is a resolutely new scientific field
combining cell culture advances with a better knowledge
of the various extracellular matrix (ECM) components.
Tissue-engineered models have numerous potential ad-
vantages over existing models, including cultivation in
three dimensional (3D) geometries, which allows cell-
cell as well as cell-ECM interactions and impact cell fate
decisions, cell proliferation and survival, and other spe-
cialized functions [29]. It is well known that cells grown
using a 3D cell culture technique more closely mimic
natural tissues and organs than cells grown in 2D [30].
For instance, our results revealed that re-expression of
disease phenotypes can be detected in the ALS-TES and
not in standard 2D cell culture. Interestingly, genes asso-
ciated with cell–matrix adhesion and cell–substrate ad-
hesion were found to be misexpressed in SALS patients
[31]. By extrapolation, we can imagine that the disrup-
tion of cell to matrix interaction detected in our ALS-
TES could also reflect an ECM misorganization within
the CNS, and adversely affect motor neurons, glia or
other neurons. Cell–matrix interactions are critical for
neuronal migration, which occurs primarily during de-
velopment as neural progenitor cells migrate to their
proper positions before differentiating [32]. Abnormal
cell–matrix interactions could therefore alter the normal
formation and wiring of the nervous system that could
also lead to disease [33]. Disruption of cell-ECM interac-
tions in the CNS could result in dysfunction of both
neuronal and non-neuronal cell categories supporting
the non-cell autonomous paradigm in ALS [15,18,20].
Accumulating evidence also indicates that matrix metal-
loproteinases (MMPs), able to degrade ECM proteins,
are involved in the pathogenesis of a number of CNS
disorders, and plays a major role in motor neuron de-
generation both in patients and in different ALS mousemodels [34-37]. The MMP genes are transcriptionally
responsive to a wide variety of growth factors, cytokines,
and reactive oxygen species. In the CNS, MMPs are syn-
thesized by neurons, astrocytes, and microglia [38,39].
Although the cause of ALS remains obscure, potential
roles of MMPs have been extensively investigated. In the
developing CNS, MMPs are involved in neurogenesis,
axonal guidance, and growth, myelinogenesis and angio-
genesis. In the adult CNS they play a role in remodeling
of the ECM, cell migration, and survival, in synaptic
plasticity with an impact on learning and memory func-
tion, myelin turnover, and angiogenesis. Our study raises
the question whether our ALS-TES may offer an easily
accessible source of biomarkers that could allow moni-
toring specific aspects of disease pathology in ALS. Fur-
ther studies investigating in parallel skin and neuronal
tissue samples are necessary to confirm this hypothesis
and to prove that the ECM-related abnormalities de-
tected in our ALS-TES may also reflect systemic changes
also present in the CNS.Conclusions
Since neurodegenerative diseases are becoming a serious
concern for many countries, early therapy and disease
prevention is essential. Diagnosis and management of
neurodegenerative disorders such as Alzheimer’s disease,
Parkinson’s disease, or ALS are currently central chal-
lenges in clinical neurology. While differing in clinical
presentations, genetic predisposing factors or histopa-
thological substrates, all these neurological disorders are
characterized by progressive and relentless loss of neur-
onal cell populations within the CNS, leading to severe
neurological deficits. While each neurodegenerative dis-
order has its own distinctive characteristics, it is well
recognized that there is an overlap between various
disorders, both in clinical presentations and in histo-
pathological features including skin changes over the
disease course [22]. Conceivably, the application of tissue-
engineered skin models to facilitate the identification of
biomarkers for early diagnosis and disease progression will
become highly attractive and will be of high importance
for the future research, allowing monitoring of patients
longitudinally. Such cross-disease biomarkers are cur-
rently not available in clinical neurological practice.
However, our study is the first to show that TDP-43
and ECM-related pathology can be reproducibly ana-
lyzed using biopsies from a peripheral tissue in living
patients. To validate the present findings and to strengthen
our results, a larger sample of ALS and control subjects
will first be required. Then, correlations between the in-
creased TDP-43 expression and/or mislocalization found
in our ALS-TES, and disease severity, survival, age of onset
and progression could then be determined in order to
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Hopefully, routine skin biopsies will become a useful
tool for ante-mortem neuropathological diagnosis of
ALS and other neurodegenerative diseases, and also
provides insight into the progression of motor and non-
motor symptoms. The use of the skin biopsies and/or
tissue-engineered skins as a window into the CNS repre-
sents an original approach with implications that may well
extend beyond ALS.Additional files
Additional file 1: Table S1. Revised El Escorial criteria for
diagnosing ALS.
Additional file 2: Figure S1. Familial C9orf72-linked ALS pedigree.
Genotypes of analyzed family members are indicated (Squares denote
males, circles-females, black symbols- affected individuals, symbols with
central dot-unaffected mutation carriers, slash marks-deceased
individuals). The numbers to the upper right of individual family
members indicate age at death/current age).
Additional file 3: Figure S2. Tissue-engineered skin equivalent using
self-assembly method. Cultured fibroblasts at passage 3, grown in DMEM
(Dulbecco-Vogt modification of Eagle's medium) (Invitrogen, Burlington,
ON, Canada) supplemented with 10% Fetal Calf Serum (FCS) (Invitrogen),
100 IU/ml penicillin G (Sigma, Oakville, QC, Canada) and 25 μg/ml
gentamicin (Schering, Pointe-Claire, QC, Canada) in 8% CO2 at 37°C,
at passage five were seeded at a concentration of 3 × 104 cells/cm2 on
tissue culture dishes. At confluence, cultured media was supplemented
with 50 μg/ml of ascorbic acid (Sigma) for 20 days in order to induce
secretion of extracellular matrix proteins and to form a fibroblast sheet.
Three fibroblast sheets are superimposed for 3 additional days to allow
sheet adhesion. Epithelial cells (isolated keratinocytes), were cultured in a
combination of Dulbecco-Vogt modification of Eagle's medium with
Ham's F12 (3:1) supplemented with 5% Fetal Clone II serum (Hyclone,
Scarborough, Ontario, Canada), 5 μg/mL insulin (Sigma Oakville, Canada),
0.4 μg/mL hydrocortisone (Calbiochem, EMD Biosciences, Gibbstown, NJ),
10 − 10 M cholera toxin (MP Biomedicals, Montréal, Québec, Canada),
10 ng/mL human epidermal growth factor (Austral Biological, San Ramon,
CA), 100 IU/mL penicillin G (Sigma), and 25 μg/mL gentamicin (Schering),
are seeded on top of the mature fibroblast sheets at a concentration of
8 × 103 cells/cm2 . The reconstructed skin equivalent is then cultivated
at the air-liquid interface in order to enhance formation of the stratum
corneum (outermost layer of the epidermis). The duration of each
maturation phases is 7 days.
Additional file 4: Table S2. Abnormal structural skin features detected
in ALS-tissue engineered skin.
Additional file 5: Figure S3. Cytoplasmic TDP-43 accumulation detected
in SALS-derived tissue-engineered skins. Indirect immunofluorescence
and confocal analysis using anti-TDP43 antibody (green) counterstained
with DAPI (blue) revealed cytoplasmic TDP-43 accumulation and an
obvious increase in TDP-43 expression specifically in SALS-derived skins.
Note that representative pictures of 50-um thick tissue-sections were
stained and visualized using a confocal microscopy, taken from one
Control- and SALS-derived skins are illustrated. Each picture was taken
using the same microscope, camera and exposure settings.
Additional file 6: Figure S4. Original Western blots and specificity of
the protein fractionation method. A) Western blot analysis revealed that,
using anti-nuclei (nuclear fraction) anti-GAPDH antibody (mainly
cytoplasmic fraction) antibodies, revealed that our cytoplasmic fraction
was completely free of nuclear protein. This clearly indicates that the
detected cytolasmic TDP-43 signal was not due to a contamination
of the fraction with nuclear proteins. B) Original Western blots,
immunostained with anti-TDP43 and anti-actin antibodies, used to
quantify the normalized TDP-43 signal.Additional file 7: Figure S5. Cytoplasmic TDP-43 inclusions are
detected in the fibroblast cells of SALS native skins. Indirect
immunofluorescence analysis, using anti-TDP-43 (red) and anti-vimentin
(green), counterstained with DAPI (blue), confirmed that the TDP-43
mislocalization is detected in fibroblast cells at the dermo-epidermal
junction and in the dermis of SALS native skins (white arrows).
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